Freedom Analysts: Eli Lilly and Johnson & Johnson are Expanding Their Oncology Portfolios
Stock Market News
16 June 2026, 19:51
Pharmaceutical companies Eli Lilly (LLY) and Johnson & Johnson (JNJ) have reported strong clinical data for new treatments targeting blood disorders, including multiple myeloma, a type of blood cancer, according to Freedom Broker analysts.
Eli Lilly is one of the world's largest pharmaceutical companies, producing medications for the treatment of diabetes, obesity, cancer, and other diseases. Johnson & Johnson is a renowned manufacturer of pharmaceuticals and medical devices. The company is a leader in the treatment of multiple myeloma.
Eli Lilly presented the initial trial results for AJ1-11095, which the company gained through its acquisition of biotech firm Ajax Therapeutics in a deal valued at up to $2.3 billion. The drug is intended for the treatment of myelofibrosis, a rare bone marrow disorder that disrupts blood cell production.
In clinical trials, 70% of patients achieved significant spleen volume reduction - a key efficacy marker in myelofibrosis treatment. Analysts note this outcome outperforms many existing therapies and validates the strategic rationale behind the Ajax Therapeutics acquisition.
Johnson & Johnson presented results for TALVEY in combination with DARZALEX FASPRO. The trials were conducted among patients with multiple myeloma whose disease continued to progress after previous treatment.
The trial demonstrated that the new treatment regimen reduced the risk of disease worsening or death by 72% compared to standard treatment. Two years after starting treatment, more than 81% of patients remained progression-free, compared to 51% in the standard treatment group. Overall survival reached 89% versus 79%.
According to Freedom analysts, the results from both companies confirm the high potential of new blood cancer treatments. For Eli Lilly, the successful trials were important confirmation of the Ajax Therapeutics acquisition efficiency. For Johnson & Johnson, the new data strengthens the company's leadership position in the multiple myeloma market and provides a basis for the use of new drugs in earlier stages of therapy.
Not an individual investment recommendation.